Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 6, 1999, Pages 495-500

  Le Marchand, Loïc ^a   Wilkinson, Grant R ^b   Wilkens, Lynne R ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CHLORZOXAZONE; CYTOCHROME CYP2E1; CYTOCHROME P450; NITROSAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER RISK; DIETARY INTAKE; ENZYME ANALYSIS; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INDIVIDUALITY; MALE; NORMAL HUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; UNITED STATES; VEGETABLE;

ADULT; AGED; ANALYSIS OF VARIANCE; ASIAN AMERICANS; BIOTRANSFORMATION; CARCINOGENS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DIET; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAWAII; HUMANS; JAPAN; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NEOPLASMS; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REGRESSION ANALYSIS;

EID: 0033048246     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Yang, C. S., Yoo, J. S. H., Ishizaki, H., and Hong, J. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab. Disp., 22: 147-159, 1990.
2. Yamazaki, H., Inui, Y., Yun, C. H., Guengerich, F. P., and Shimada, T. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis (Lond.), 13: 1789-1794, 1992.
3. Hecht, S. S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Res. Toxicol., 11: 560-603, 1998.
4. Guengerich, F. P, Kim, D-H., and Iwasaki, M. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4: 168-179, 1991.
5. Ronis, M. J. J., Lindros, K. O., and Ingelman-Sundberg, M. The CYP2E1 subfamily. In: C. Ioannides (ed.), Cytochromes P450: Metabolic and Toxicological Agents, pp. 212-239. Boca Raton, FL: CRC Press, 1996.
6. Lieber, C. S. Mechanisms of ethanol-drug nutrition interactions. Clin. Toxicol., 32: 631-681, 1994.
7. Yoo, J. S. H., Guengerich, F. P., and Yang, C. S. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res., 48: 1499-1504, 1988.
8. Hunt, C. M., Strater, S., and Stave, E. M. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem. Pharmacol., 10: 1666-1669, 1990.
9. Kim, R. B., O'Shea, D., and Wilkinson, G. R. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther., 57: 645-655, 1995.
10. Girre, C., Lucas, D., Hispard, E., Menez, C., Dally, S., and Menez, J-F. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol., 47: 1503-1508, 1994.
11. O'Shea, D., Davis, S. N., Kim, R. B., and Wilkinson, G. R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin. Pharmacol. Ther., 56: 359-367, 1994.
12. Dilger, K., Metzler, J., Bode, J. C., and Klotz, U. CYP2E1 activity in patients with alcoholic liver disease. J. Hepatol., 27: 1009-1014, 1997.
13. Kharasch, E. D., Thummel, K. E., Mhyre, J., and Lillibridge, J. H. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin. Pharmacol. Ther., 53: 643-650, 1993.
14. Gerhardt, A. C., Lucas, D., Ménez, J-F., and Seitz, H. K. Chlormethiazole inhibition of cytochrome P4502E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology, 26: 957-961, 1997.
15. Eap, C. B., Schnyder, C., Besson, J., Savary, L., and Buclin, T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin. Pharmacol. Ther., 64: 52-57, 1998.
16. Leclercq, I., Desago, J-P., and Horsman, Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin. Pharmacol. Ther., 64: 144-149, 1998.
17. Uematsu, F., Kikuchi, H., Ohmachi, T., Sagami, I., Motomiya, M., Kamataki, T., Komori, M., and Watanabe, M. Two common RFLPs of the human CYP2E1 gene. Nucleic Acids Res., 19: 2803, 1991.
18. Carrière, V., Berthou, F., Baird, S., Belloc, C., Beaune, P., and deWaziers, I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6: 203-211, 1996.
19. Powell, H., Kitteringham, N. R., Pirmohamed, M., Smith, D. A., and Park, B. K. Expression of cytochrome P4502E1 (CYP2E1) in human liver: assessment of mRNA, genotype and phenotype. Pharmacogenetics, 8: 411-421, 1998.
20. Lucas, D., Menez, C., Girre, C., Berthou, F., Bodenez, P., Joannet, I., Hispard, E., Bardou, L-G., and Menez, J-F. Cytochrome P4502E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5: 298-304, 1995.
21. Kim, R. B., Yamazaki, H., Chiba, K., O'Shea, D., Minura, M., Guengerich, F. P., Ishizaki, T., Shimada, T., and Wilkinson, G. R. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J. Pharmacol. Exp. Ther., 279: 4-11, 1996.
22. Hayashi, S., Watanabe, J., and Kawajiri, K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P4502E1 gene. J. Biochem., 110: 559-565, 1991.
23. Watanabe, J., Hayashi, S-I., and Kawajiri, K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem., 116: 321-326, 1994.
24. Le Marchand, L., Wilkens, L. R., and Kolonel, L. N. Ethnic differences in the lung cancer risk associated with smoking. Cancer Epidemiol. Biomark. Prev., 1: 103-107, 1992.
25. Le Marchand, L., and Kolonel, L. N. Cancer among Japanese migrants to Hawaii: gene-environment interactions. Rev. Epidemiol. Sante Publique, 40: 425-430, 1992.
26. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., and Watanabe, M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. Cancer Res., 82: 254-256, 1991.
27. Wu, X., Shi, H., Jiang, H., Kemp, B., Hong, W. K., Delclos, G. L., and Spitz, M. R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis (Lond.), 18: 967-973, 1997.
28. Wu, X. F., Amos, C. I., Kemp, B. L., Shi, H. H., Jiang, H., Wan, Y., and Spitz, M. R. Cytochrome P450 2E1 DraI polymorphism in lung cancer in minority populations. Cancer Epidemiol. Biomark. Prev., 7: 13-18, 1998.
29. Le Marchand, L., Sivaraman, L., Pierce, L., Seifried, A., Lum, A., Wilkens, L. R., and Lau, A. F. Associations of CYP1A1, GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res., 58: 4858-4863, 1998.
30. Le Marchand, L., Sivaraman, L., Pierce, L. M., Seifried, A., Lum, A., Franke, A. A., Custer, L. J., and Nerurkar, P. V. Gene-diet interactions and the high colorectal cancer risk of Japanese-Americans. Proceedings of the UICC Symposium on Familial Cancer and Prevention-Molecular Epidemiology: A New Strategy Towards Cancer Control. New York: John Wiley & Sons, in press, 1999.
31. United States Department of Agriculture. Nutrient Data Base for Standard Reference, Release 10. Bethesda, MD: Human Nutrition Information Service, USDA, 1992.
32. Willett, W. C., and Stampfer, M. J. Total energy intake: implications for epidemiologic analyses. Am. J. Epidemiol., 124: 17-27, 1986.
33. Frye, R. F., Adedoyin, A., Mauro, K., Matzke, G. R., and Branch, R. A. Use of chlorzoxazone as in vivo probe of cytochrome P4502E1: choice of dose and phenotypic trait measure. J. Clin. Pharmacol.m 38: 82-89, 1998.
34. O'Shea, D., Kim, R. B., and Wilkinson, G. R. Modulation of CYP2E1 activity by isoniazid in fast and slow acetylators. Br. J. Clin. Pharmacol., 43: 99-103, 1997.
35. Nawaratne, S., Brien, J. E., Seeman, E., Fabiny, R., Zalcbery, J., Cosolo, W., Angus, P., and Morgan, D. J. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br. J. Clin. Pharmacol., 46: 447-452, 1998.
36. Yoo, J-S. H., Smith, T. J., Ning, S. M., Lee, M-J., Thomas, P. E., and Yang, C. S. Modulation of the levels of cytochrome P450 in rat liver and lung by dietary lipid. Biochem. Pharmacol., 43: 2535-2542, 1992.
37. Takahashi, H., Johansson, I., French, S. W., and Ingelman-Sundberg, M. Effect of dietary fat composition on activities of the microsomal ethanol oxidizing system and ethanol-inducible cytochrome P450 (CYP2E1) in the liver of rats chronically fed ethanol. Pharmacol. Toxicol., 70: 347-352, 1992.
38. Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., Western, A., and Harris, C. C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res., 52: 6712-6715, 1992.
39. Stephens, E. A., Taylor, J. A., Kaplan, N., Yang, C-H., Hsieh, L. L., Lucier, G. W., and Bell, D. A. Ethnic variability in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4: 185-192, 1994.
40. Hirvonen, A., Husgafvel-Pursiainen, K., Antilla, S., Karjalainen, A., and Vainio, H. The human CYP2E1 gene and lung cancer: Dra1 and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis (Lond.), 14: 85-88, 1993.
41. Persson, I., Johansson, I., Bergling, H., Dahl, M-L., Seidegard, J., Rylander, R., Rannug, A., Hogberg, J., and Sundberg, M. I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to incidence of lung cancer. FEBS Lett., 319: 207-211, 1993.
42. Kato, S., Shields, P. G., Caporaso, N. E., Sugimura, H., Trivers, G. E., Tucker, M. A., Trump, B. F., Weston, A., and Harris, C. C. Analysis of cytochrome P4502E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomark. Prev., 3: 515-518, 1994.
43. El-Zein, R. A., Zwischenberger, J. B., Abdel-Rahman, S. Z., Sankar, A. B., and Au, W. W. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett., 112: 71-78, 1997.
44. Yu, M-W., Gladek-Yarborough, A., Chiamprasert, S., Santella, R. M., Liaw, Y-F., and Chen, C-J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology, 109: 1266-1273, 1995.
45. Lin, D-X., Tang, Y-M., Peng, Q., Lu, S-X., Ambrosone, C. B., and Kadlubar, F. F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol. Biomark. Prev., 7: 1013-1018, 1998.
46. London, S. J., Daly, A. K., Cooper, J., Carpenter, C. L., Navidi, W. C., Ding, L., and Idle, J. R. Lung cancer risk in relation to CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics, 6: 151-158, 1996.
47. Watanabe, J., Yang, J-P., Eguchi, H., Hayashi, S., Imai, K., Nakachi, K., and Kawajim, K. An RsaI polymorphism in the CYP2E1 gene does not affect lung cancer risk in Japanese population. Jpn. J. Cancer Res., 86: 245-248, 1995.
48. Block, G., Patterson, B., and Subar, A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer. 18: 1-29, 1992.
49. Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res., 52: 2085s-2091s, 1992.
50. Yang, C. S., Brady, J. F., and Hong, J-Y. Dietary effects on cytochromes P450. xenobiotic metabolism, and toxicity. FASEB J., 6: 737-744, 1992.
51. Barcelo, S., Gardiner, J. M., Gescher, A., and Chipman, J. K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis (Lond.), 17: 277-282, 1996.
52. Ishizaki, H., Brady, J. F., Ning, S. M., and Yang, C. S. Effect of phenethyl isothiocyanate on microsomal N-nitrosodimethyl amine metabolism and other monooxygenase activities. Xenobiotica, 20: 255-264, 1990.
53. Brady, J. F., Ishizaki, H., Fukoto, J. M., Lin, M. C., Fadel, A., Gapac, J. M., and Yang, C. S. Inhibition of cytochrome P-4502E1 by diallylsulfide and its metabolites. Chem. Res. Toxicol., 4: 642-647, 1991.
54. Kwak, M. Y., Kim, S. G., Kwak, J. Y., Novak, R. F., and Kim, N. D. Inhibition of cytochrome P4502E1 expression by organosulfur compounds allylsulfide allylmercaptan and allylmethylsulfide in rats. Biochem. Pharmacol., 47: 531-539, 1994.
55. Shi, S. T., Wang, Z-T., Smith, T. J., Hong, J-Y., Chen, W-F., Ho, C-T., and Yang, C. S. Effects of green tea and black tea on 4-(methynitrosoamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation and lung tumorigenesis in A/J mice. Cancer Res., 54: 4641-4647, 1994.
56. Kall, M. A., Vang, D., and Clausen, J. Effects of dietary broccoli or human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis (Lond.), 17: 793-799, 1996.